These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 35518387)

  • 21. Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium.
    Bernstein CD; Albrecht KL; Marcus DA
    Expert Opin Pharmacother; 2013 May; 14(7):905-16. PubMed ID: 23506481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inactivation of yeast hexokinase by o-phthalaldehyde: evidence for the presence of a cysteine and a lysine at or near the active site.
    Puri RN; Bhatnagar D; Roskoski R
    Biochim Biophys Acta; 1988 Nov; 957(1):34-46. PubMed ID: 3140897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Milnacipran: a selective serotonin and norepinephrine dual reuptake inhibitor for the management of fibromyalgia.
    Palmer RH; Periclou A; Banerjee P
    Ther Adv Musculoskelet Dis; 2010 Aug; 2(4):201-20. PubMed ID: 22870448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Milnacipran for pain in fibromyalgia in adults.
    Cording M; Derry S; Phillips T; Moore RA; Wiffen PJ
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD008244. PubMed ID: 26482422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.
    Puech A; Montgomery SA; Prost JF; Solles A; Briley M
    Int Clin Psychopharmacol; 1997 Mar; 12(2):99-108. PubMed ID: 9219045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Milnacipran, a new specific serotonin and noradrenaline reuptake inhibitor.
    Boyer P; Briley M
    Drugs Today (Barc); 1998 Aug; 34(8):709-20. PubMed ID: 14988777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An efficient spectrofluorimetric method adopts doxazosin, terazosin and alfuzosin coupling with orthophthalaldehyde: Application in human plasma.
    Omar MA; Mohamed AI; Derayea SM; Hammad MA; Mohamed AA
    Spectrochim Acta A Mol Biomol Spectrosc; 2018 Apr; 195():215-222. PubMed ID: 29414581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized-controlled trial.
    Ang DC; Jensen MP; Steiner JL; Hilligoss J; Gracely RH; Saha C
    Clin J Pain; 2013 Sep; 29(9):747-54. PubMed ID: 23446065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome.
    Häuser W; Urrútia G; Tort S; Uçeyler N; Walitt B
    Cochrane Database Syst Rev; 2013 Jan; (1):CD010292. PubMed ID: 23440848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An open-label clinical trial of milnacipran in fibromyalgia syndrome with co-morbid depressive symptoms.
    Nagaoka S; Ohno M; Sekiguchi A
    Int J Psychiatry Clin Pract; 2004; 8(1):47-51. PubMed ID: 24937583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
    Li F; Chin C; Wangsa J; Ho J
    Drug Metab Dispos; 2012 Sep; 40(9):1723-35. PubMed ID: 22653299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Milnacipran for treatment of fibromyalgia.
    Kyle JA; Dugan BD; Testerman KK
    Ann Pharmacother; 2010 Sep; 44(9):1422-9. PubMed ID: 20716692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spectrofluorimetric determination of oseltamivir phosphate through derivatization with o-phthalaldehyde. Application to pharmaceutical preparations with a preliminary study on spiked plasma samples.
    Walash MI; Belal F; El-Enany N; El-Maghrabey MH
    Luminescence; 2012; 27(6):511-8. PubMed ID: 22362604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid fluorometric determination of ticagrelor in tablets and rat plasma: Application to pharmacokinetics study.
    Elmansi H; Zayed S; Belal F
    Spectrochim Acta A Mol Biomol Spectrosc; 2020 Dec; 242():118722. PubMed ID: 32763840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of the nature of o-phthalaldehyde reaction with octopine dehydrogenase.
    Sheikh S; Katiyar SS
    J Enzyme Inhib; 1994; 8(1):39-50. PubMed ID: 7539068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Milnacipran: beyond a role of antidepressant.
    Pae CU; Marks DM; Shah M; Han C; Ham BJ; Patkar AA; Masand PS
    Clin Neuropharmacol; 2009; 32(6):355-63. PubMed ID: 19620845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia.
    Vitton O; Gendreau M; Gendreau J; Kranzler J; Rao SG
    Hum Psychopharmacol; 2004 Oct; 19 Suppl 1():S27-35. PubMed ID: 15378666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Milnacipran: in fibromyalgia.
    Chwieduk CM; McCormack PL
    Drugs; 2010; 70(1):99-108. PubMed ID: 20030428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain.
    Obata H; Saito S; Koizuka S; Nishikawa K; Goto F
    Anesth Analg; 2005 May; 100(5):1406-1410. PubMed ID: 15845695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical pharmacology of milnacipran.
    Briley M; Prost JF; Moret C
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():9-14. PubMed ID: 8923122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.